Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

May 5, 2017May 5, 2017

Kevzara Takes Step Toward EU Approval, While FDA Decision Is Expected in May

News, rheumatoid arthritis

Kevzara (sarilumab) has received a thumbs-up from the European Medicine Agency (EMA), which has recommended that the European Commission approve it to treat adults with moderate to severe rheumatoid arthritis, according ... Read more

February 13, 2017February 13, 2017

Newly Identified Genes May Contribute to Arthritis Risk in Arabs, Study Shows

News

A large genetic study confirmed that Arabs share a rheumatoid arthritis risk gene with other populations, but identified new genes that may be involved in triggering the disease in Arabs ... Read more

February 6, 2017February 6, 2017

Newly Identified T-cell in RA Patients May Leapfrog Autoimmune Treatment Development

News, rheumatoid arthritis

An entirely new type of T-cell found in people with rheumatoid arthritis works in a unique way to drive disease processes in the joints by teaming up with other immune ... Read more

December 9, 2016December 9, 2016

T-cells May Predict Rituxan Treatment Response in RA Patients

News, rheumatoid arthritis

Rheumatoid arthritis patients who benefit from Rituxan (rituximab) have a distinctive drop in T-cells after treatment — a change that corresponds to an improvement in symptoms. The findings show that counts ... Read more

November 28, 2016November 28, 2016

Chronic Inflammation May Explain Heart Disease in Rheumatoid Arthritis

News, rheumatoid arthritis

Patients with rheumatoid arthritis have chronic inflammation in the heart, which may explain the common occurrence of heart disease in this patient group. The good news is it may be ... Read more

November 22, 2016November 22, 2016

Clinical Data Support Phase 3 Trials of Olokizumab for Rheumatoid Arthritis, R-Pharm Reports

News

R-Pharm recently reported positive results from Phase 2 clinical trials of olokizumab for the treatment of rheumatoid arthritis, supporting the drug’s move into Phase 3 testing now underway. The data was presented ... Read more

October 21, 2016October 21, 2016

Ablynx Concludes Phase 2 Trials of RA Therapy, Losing Partner AbbVie in the Process

News

Ablynx is about to wrap up its Phase 2 trials of vobarilizumab (ALX-0061) for patients with rheumatoid arthritis, and is discussing a move toward Phase 3 studies with U.S. and European ... Read more

October 17, 2016October 17, 2016

Early Rheumatoid Arthritis, Bone Loss Linked to Autoantibodies

News

The presence of certain autoantibodies in rheumatoid arthritis (RA) is linked to bone loss in patients with early disease, suggesting that bone remodeling in rheumatoid arthritis is directly connected to autoimmunity. ... Read more

October 5, 2016October 5, 2016

Stimulating Environment Boosted Immune System in Mice; RA applications envisioned

News

It may be possible to boost the immune system simply by staying in a stimulating environment, according to a study that showed giving mice more toys and space for two ... Read more

June 10, 2016June 10, 2016

#EULAR2016 – Smoking and Obesity in RA Patients Reduces Chance of Reaching Sustained Remission

News

Smoking and obesity in patients with rheumatoid arthritis (RA) are factors preventing patients from reaching sustained remission, according to findings presented at the European League Against Rheumatism Annual Congress (EULAR 2016) June ... Read more